Arcellx Inc. (ACLX), which reported positive preliminary data from its pivotal iMMagine-1 study in May of this year, is scheduled to present updated data next month.
The iMMagine-1 is a phase 2 study evaluating the company's lead investigational product, Anitocabtagene autoleucel (anito-cel), in patients with relapsed or refractory multiple myeloma. Anito-cel is an autologous anti-B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T-cell therapy that belongs to the same class as Johnson & Johnson/Legend's Carvykti and Bristol Myers Squibb's Abecma, which are approved for relapsed or refractory (R/R) multiple myeloma (MM).
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com